EGFR and non-small cell lung carcinoma: Osimertinib (OSI), a third-generation EGFR TKI, was developed for the treatment of patients with EGFR exon 20 T790M mutation-positive NSCLC, after the failure of the first- and second-generation EGFR TKIs.9